Letter to the Editor: Re: Aspartate aminotransferase-to-platelet ratio index (APRi) as biomarker for liver damage in biliary atresia (BA): a meta-analysis

jpedsurg.org

I appreciate the authors’ thoughtful response to my letter and their effort to clarify the methodological scope of their meta-analysis on APRi in biliary atresia [1]. I fully recognize the clinical relevance of the topic and the challenges of synthesizing heterogeneous data. My comments are intended to improve methodological transparency and interpretive consistency. I thank the authors for their clarifications, which help delineate the boundaries of their analytical approach.

jpedsurg.org shows its articles on its own site.

Read the article on jpedsurg.org ↗

Article · Jul 2025 · 1 min read

In brief

This correspondence addresses methodological considerations in a meta-analysis evaluating APRi (aspartate aminotransferase-to-platelet ratio index) as a non-invasive biomarker for liver damage in biliary atresia. The author emphasizes the importance of methodological transparency and interpretive consistency when synthesizing heterogeneous clinical data in pediatric hepatology.

Methodological transparency is essential when synthesizing heterogeneous data in pediatric liver disease meta-analyses.
APRi biomarker studies in biliary atresia require clear analytical boundaries to ensure valid clinical interpretation.
Constructive peer dialogue strengthens the rigor and reproducibility of hepatobiliary research in children.

Written by the GCMD Library team from the article.

Read it at the source ↗